Moderna’s New COVID-19 Vaccine Elicits Strong Immune Response in Phase 3 Trial
The phase 3 NextCOVE study compared the safety, reactogenicity, relative vaccine efficacy and immunogenicity of mRNA-1283 to Moderna’s licensed COVID-19 vaccine, Spikevax.